Literature DB >> 18978820

Patient socioeconomic status as a prognostic factor for allo-SCT.

L Silla1, G B Fischer, A Paz, L E Daudt, I Mitto, B Katz, M da Graça Grossini, H N Bittencourt, A Jochims, L Fogliatto, C M Bittar, J R Friedrisch, R I Bittencourt.   

Abstract

The aim of the present study was to assess the influence of socioeconomic status (SeS) on the outcome of allo-SCT at a Brazilian SCT center. In total, 201 patients receiving HLA-identical related allo-SCTs were studied. The median age was 30 years. Overall, 163 patients had malignancies (CML 68, ALL/AML 63, myelodysplastic syndrome 12 and others 20). SeS was defined according to the Brazilian Association of Market Research Agencies classification, where people are clustered in groups A-E (richest to poorest). In total, 146 patients (72%) were classified as richest (A+B+C) and 55 (28%) as poorest (D+E). The D+E SeS group was associated with a higher incidence of chronic GVHD and acute GVHD (hazard ratio (HR)=2.61; P=0.001 and HR=2.62; P=0.001, respectively), better platelet and neutrophil engraftment (HR=1.94; P=<0.001 and HR=2.12; P=0.001) and with a higher TRM in multivariate analysis (HR=1.92; P=0.039). Estimated overall survival at 5 years was 55.2%. A D+E SeS (HR=2.13; P=0.001) was associated with a worse survival on multivariate analysis. In conclusion, a lower SeS is a strong prognostic factor in patients undergoing allo-SCT in Brazil, influencing engraftment, TRM and overall survival.

Entities:  

Mesh:

Year:  2008        PMID: 18978820     DOI: 10.1038/bmt.2008.358

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN: 0268-3369            Impact factor:   5.483


  11 in total

1.  Association of socioeconomic status with long-term outcomes in 1-year survivors of allogeneic hematopoietic cell transplantation.

Authors:  S Fu; L Rybicki; D Abounader; S Andresen; B J Bolwell; R Dean; A Gerds; B K Hamilton; R Hanna; B T Hill; D Jagadeesh; M E Kalaycio; H D Liu; B Pohlman; R M Sobecks; N S Majhail
Journal:  Bone Marrow Transplant       Date:  2015-07-20       Impact factor: 5.483

2.  Is It Better to Be Rich or Relaxed? Sociobiology Meets Bone Marrow Transplant.

Authors:  Lucie M Turcotte; Michael R Verneris
Journal:  Clin Cancer Res       Date:  2015-10-19       Impact factor: 12.531

3.  Practice variation in physician referral for allogeneic hematopoietic cell transplantation.

Authors:  J Pidala; B M Craig; S J Lee; N Majhail; G Quinn; C Anasetti
Journal:  Bone Marrow Transplant       Date:  2012-06-18       Impact factor: 5.483

4.  Association of Socioeconomic Status with Chronic Graft-versus-Host Disease Outcomes.

Authors:  Betty K Hamilton; Lisa Rybicki; Sally Arai; Mukta Arora; Corey S Cutler; Mary E D Flowers; Madan Jagasia; Paul J Martin; Jeanne Palmer; Joseph Pidala; Navneet S Majhail; Stephanie J Lee; Nandita Khera
Journal:  Biol Blood Marrow Transplant       Date:  2017-10-12       Impact factor: 5.742

5.  Patient-Reported Outcomes and Socioeconomic Status as Predictors of Clinical Outcomes after Hematopoietic Stem Cell Transplantation: A Study from the Blood and Marrow Transplant Clinical Trials Network 0902 Trial.

Authors:  Jennifer M Knight; Karen L Syrjala; Navneet S Majhail; Michael Martens; Jennifer Le-Rademacher; Brent R Logan; Stephanie J Lee; Paul B Jacobsen; William A Wood; Heather S L Jim; John R Wingard; Mary M Horowitz; Muneer H Abidi; Mingwei Fei; Laura Rawls; J Douglas Rizzo
Journal:  Biol Blood Marrow Transplant       Date:  2016-08-23       Impact factor: 5.742

6.  Low Socioeconomic Status, Adverse Gene Expression Profiles, and Clinical Outcomes in Hematopoietic Stem Cell Transplant Recipients.

Authors:  Jennifer M Knight; J Douglas Rizzo; Brent R Logan; Tao Wang; Jesusa M G Arevalo; Jeffrey Ma; Steve W Cole
Journal:  Clin Cancer Res       Date:  2015-08-18       Impact factor: 12.531

7.  Race/ethnicity affects the probability of finding an HLA-A, -B, -C and -DRB1 allele-matched unrelated donor and likelihood of subsequent transplant utilization.

Authors:  J Pidala; J Kim; M Schell; S J Lee; R Hillgruber; V Nye; E Ayala; M Alsina; B Betts; R Bookout; H F Fernandez; T Field; F L Locke; T Nishihori; J L Ochoa; L Perez; J Perkins; J Shapiro; C Tate; M Tomblyn; C Anasetti
Journal:  Bone Marrow Transplant       Date:  2012-08-06       Impact factor: 5.483

Review 8.  Unmet Needs for Psychosocial Care in Hematologic Malignancies and Hematopoietic Cell Transplant.

Authors:  Anna Barata; William A Wood; Sung Won Choi; Heather S L Jim
Journal:  Curr Hematol Malig Rep       Date:  2016-08       Impact factor: 3.952

9.  Immunosuppressive serum levels in allogeneic hematopoietic stem cell transplantation: pharmaceutical care contribution.

Authors:  Paulo M Corrêa; Joice Zuckermann; Gustavo B Fischer; Mauro S Castro
Journal:  Pharm Pract (Granada)       Date:  2016-06-15

10.  Molecular Correlates of Socioeconomic Status and Clinical Outcomes Following Hematopoietic Cell Transplantation for Leukemia.

Authors:  Jennifer M Knight; J Douglas Rizzo; Tao Wang; Naya He; Brent R Logan; Stephen R Spellman; Stephanie J Lee; Michael R Verneris; Jesusa M G Arevalo; Steve W Cole
Journal:  JNCI Cancer Spectr       Date:  2019-09-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.